IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1410 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded436    
    Comments [Add]    
    Cited by others 6    

Recommend this journal


Year : 2010  |  Volume : 42  |  Issue : 6  |  Page : 362-365

A comparative study on the efficacy, safety, and cost-effectiveness of bimatoprost/timolol and dorzolamide/timolol combinations in glaucoma patients

1 RVS College of Pharmaceutical Sciences, Sulur, Coimbatore-641 402, Tamilnadu, India
2 Department of Pharmacy Practice, Periyar College of Pharmaceutical Sciences for Girls, Trichirappalli-620 021, Tamilnadu, India

Correspondence Address:
Siddhartha Pal
Department of Pharmacy Practice, Periyar College of Pharmaceutical Sciences for Girls, Trichirappalli-620 021, Tamilnadu
Login to access the Email id

Source of Support: We thank Tamilnadu Pharmaceutical Welfare trust and Tamilnadu State Council for Science and Technology- Department of Biotechnology for providing the fund and support. We express our special thanks to Dr. Nalitha G. Maduram, Department of Glaucoma, Vasan eye care Hospital, Trichy. We also thank Mr.S.Wasim Raja for his support in the preparation of this manuscript, Conflict of Interest: None

DOI: 10.4103/0253-7613.71917

Rights and Permissions

Aim: This study was designed to compare the bimatoprost/timolol combination and dorzolamide/timolol combination in glaucoma for efficacy, safety, and cost-effectiveness in a local population of Trichy in the state of Tamilnadu. Materials and Methods: Eight-week, randomized, parallel group, open-label study was conducted on 48 patients of open angle glaucoma or ocular hypertension. After initial clinical assessment and baseline investigations, bimatoprost/timolol combination (Group A) was prescribed to 22 patients (2 patients lost after initial assessment) and dorzolamide/timolol combination (Group B) to 24 patients. The patients were reviewed after second and eighth weeks for cure rate and adverse drug reaction monitoring. Results: At the end of 8 weeks, the mean reduction in intraocular pressure from baseline was 13.04 mmHg (95% confidence interval (CI): 10.67-14.70) with bimatoprost/timolol combination once daily (P < 0.01) and 9.46 mmHg (95% CI: 7.47-10.5) with dorzolamide/timolol combination twice daily. Both the treatments were safe. Cost-effective range of bimatoprost/timolol combination was lower than that of dorzolamide/timolol combination. Conclusion: The fixed combination of bimatoprost/timolol was slightly more effective than that of dorzolamide/timolol combination in reducing IOP, and both treatments were generally well tolerated. Bimatoprost/timolol combination was more cost-effective (cost-effective analysis) than dorzolamide/timolol combination.


Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer | Privacy Notice
Online since 20th July '04
Published by Wolters Kluwer - Medknow